Acumen Pharmaceuticals (ABOS): Rasio utang jangka cendhak marang ekuitas
Acumen Pharmaceuticals (ABOS) is developing cutting-edge treatments for Alzheimer's disease, securing profitability through long-term reservation of production capacities. Business growth is driven by the potential of the ACU193 drug and global demand stemming from demographic shifts. The market price on GURU.Markets, as confirmed by the chart, shows a value of 0.56, which correlates with investor confidence in Daniel O'Connell's leadership during the antibody development phase.
Rincian analitis perusahaan Acumen Pharmaceuticals
- rega lan prakiraan konsensus rega:
- data kapitalisasi pasar:
- data kapitalisasi buku:
- data utang lan likuiditas:
Total Utang marang Modal Acumen Pharmaceuticals|ABOS - Utang jangka dawa marang modal|Utang jangka cendhak marang modal Acumen Pharmaceuticals, Inc.|ABOS - Gunggung utang perusahaan|Utang marang nilai buku Acumen Pharmaceuticals Inc.|ABOS - Utang jangka dawa perusahaan|Utang jangka cendhak perusahaan Acumen Pharmaceuticals
Analisis fundamental perusahaan:Acumen Pharma
The lack of stable cash flow due to Acumen Pharmaceuticals (ABOS) focusing on clinical stages of antibody development makes the company dependent on external financing. This chart of the short-term liabilities-to-equity ratio allows for an assessment of loans with a maturity of up to one year relative to equity, revealing risks of rising debt service costs during a period of high Fed rates and determining the stability of the capital structure.
Perusahaan pesaing
Biogen Corp - Utang jangka cendhak marang modal|Kewajiban jangka cendhak marang modal Neurocrine Corp NBIX|Rasio utang jangka cendhak marang ekuitas RGC (Regencell Bioscience)|axsome.com - Utang jangka cendhak marang modal|Utang jangka cendhak marang ekuitas ACADIA Pharmaceuticals Inc. (ACAD)|XENE: Rasio tanggungan utang jangka cendhak marang modal|Utang jangka cendhak marang ekuitas VKTX|Supernus Corp (SUPN) - Kewajiban jangka cendhak marang modal|CPRX (Catalyst Pharmaceuticals) - Utang jangka cendhak marang modal|Utang jangka cendhak marang modal denalitherapeutics.com|Utang jangka cendhak marang modal HRMY (Harmony Biosciences Holdings, Inc.)|Rasio utang jangka cendhak marang ekuitas Biohaven Ltd BHVN|Rasio utang jangka cendhak marang ekuitas AMLX (Amylyx)|Trevi Corp - Utang jangka cendhak marang modal|PRAX: Utang jangka cendhak marang ekuitas|AVXL - Rasio utang jangka cendhak marang ekuitas|Utang jangka cendhak marang modal CBLL|PRTA (Prothena Biosciences) - Kewajiban jangka cendhak marang modal|Utang jangka cendhak marang ekuitas Alector Inc. (ALEC)|Rasio utang jangka cendhak marang modal Annexon Biosciences Inc. (ANNX)|Omeros Corporation (OMER) - Rasio utang jangka cendhak marang ekuitas|Rasio tanggungan utang jangka cendhak marang modal NGNE (neurogene.com)|AC Immune SA (ACIU) - Utang jangka cendhak marang ekuitas|Kewajiban jangka cendhak marang ekuitas Voyager Therapeutics Inc VYGR|Utang jangka cendhak marang modal Neumora Therapeutics Inc (NMRA)|SCLX - Rasio tanggungan utang jangka cendhak marang modal|TVGN: Utang jangka cendhak marang modal|ACOG (Alpha Cognition Inc.) - Utang jangka cendhak marang modal|CGTX - Utang jangka cendhak marang ekuitas|Rasio tanggungan utang jangka cendhak marang modal IKT|Utang jangka cendhak marang ekuitas SAVA (Cassava)|Rasio utang jangka cendhak marang ekuitas assertiotx.com (ASRT)|Utang jangka cendhak marang modal COYA (Coya Therapeutics)|Utang jangka cendhak marang modal VistaGen Therapeutics, Inc. VTGN|OVID: Utang jangka cendhak marang modal|CRVO - Rasio utang jangka cendhak marang ekuitas|Utang jangka cendhak marang modal ATHE|Kewajiban jangka cendhak marang modal Clene|PEPG (PepGen Inc) - Rasio utang jangka cendhak marang ekuitas|Utang jangka cendhak marang modal jupiterneurosciences.com (JUNS)|Rasio utang jangka cendhak marang ekuitas Relmada Therapeutics, Inc.|Rasio silihan jangka cendhak marang modal Annovis Bio Inc (ANVS)|Utang jangka cendhak marang modal GRCE|Koefisien utang jangka cendhak marang modal Firefly Neuro AIFF|KLTO: Utang jangka cendhak marang modal|NRSN - Rasio utang jangka cendhak marang ekuitas|RVPH: Utang jangka cendhak marang modal|MTVA (MetaVia) - Utang jangka cendhak marang modal|Utang jangka cendhak marang ekuitas NeurAxis, Inc|Utang jangka cendhak marang ekuitas HSDT|PASG (Passage Bio, Inc.) - Utang jangka cendhak marang ekuitas|Koefisien utang jangka cendhak marang modal bionomics.com.au (NEUP)|Utang jangka cendhak marang modal NERV (Minerva Neurosciences, Inc.)|Utang jangka cendhak marang modal Athira Pharma Inc ATHA|ADXN - Utang jangka cendhak marang modal|ALZN: Utang jangka cendhak marang ekuitas|Utang jangka cendhak marang ekuitas CYCN|PTIX (Protagenic Therapeutics, Inc.) - Kewajiban jangka cendhak marang modal|KTTA: Utang jangka cendhak marang ekuitas|Koefisien utang jangka cendhak marang modal CRGT|Utang jangka cendhak marang ekuitas Avenue Therapeutics, Inc ATXI|Rasio utang jangka cendhak marang modal BrainStorm Cell Therapeutics Inc. (BCLI)|CARA: Utang jangka cendhak marang modal|CHRO - Kewajiban jangka cendhak marang modal|Eliem - Rasio utang jangka cendhak marang ekuitas|ITCI: Utang jangka cendhak marang modal|Utang jangka cendhak marang ekuitas Longboard Pharma LBPH|MRNS (Marinus Pharma) - Rasio tanggungan utang jangka cendhak marang modal|Utang jangka cendhak marang ekuitas NKGN (NKGen Biotech, Inc.)|Kewajiban jangka cendhak marang modal neurobopharma.com|Utang jangka cendhak marang modal SAGE|Utang jangka cendhak marang modal Synaptogenix Inc. (SNPX)|Trevena, Inc - Utang jangka cendhak marang modal|VIGL - Rasio utang jangka cendhak marang ekuitas|Anew Medical, Inc. - Rasio utang jangka cendhak marang ekuitas|CERE: Utang jangka cendhak marang modal